Other languages Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Market Closed - Nasdaq Stockholm Other stock markets 11:08:46 2024-05-17 am EDT			5-day change	1st Jan Change
0.279 ^SEK	0.00%		-7.62%	+7.31%

Apr. 30	Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	CI
Apr. 25	Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	Apr. 30
Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study	Apr. 25
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 12
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 09
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	Feb. 08
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	Nov. 14
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	23-10-25
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18
Annexin Pharmaceuticals AB Announces Success in the Cancer Initiative	23-09-29
Annexin Pharmaceuticals AB Announces Promising Signals of Effect in RVO- Study	23-08-11
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17
Annexin Pharmaceuticals AB Auditor Raises 'Going Concern' Doubt	23-04-18
Annexin Reports First Imaging- Study Results in Retinal Vein Occlusion	23-04-18
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-07
Annexin Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-07
Annexin Pharmaceuticals AB Appoints Dr. Alain Thibault as Therapeutic Area Head of Oncology	23-01-18
Annexin Pharmaceuticals Doses First Patient in Phase 2 Trial of Retinal Vein Occlusion Treatment	22-11-08
Annexin Pharmaceuticals AB Announces First Patient Dosed in Annexin's Phase 2 Study in Retinal Vein Occlusion	22-11-08
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Other languages

Filters